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Summary
Tumorigenesis requires sequential accumulation of multiple genetic lesions. In the prostate, tumor initiation is often linked
to loss of heterozygosity at the Nkx3.1 locus. In mice, loss of even one Nkx3.1 allele causes prostatic epithelial hyperplasia
and eventual prostatic intraepithelial neoplasia (PIN) formation. Here we demonstrate that Nkx3.1 allelic loss extends the
proliferative stage of regenerating luminal cells, leading to epithelial hyperplasia. Microarray analysis identified Nkx3.1
target genes, many of which show exquisite dosage sensitivity. The number of Nkx3.1 alleles determines the relative
probabilities of stochastic activation or inactivation of a given target gene. Thus, loss of a single Nkx3.1 allele likely results
in hyperplasia and PIN by increasing the probability of completely inactivating select Nkx3.1-regulated pathways within a
subset of affected cells.
Introduction ter cells, then these statistical arguments become less compel-
ling. It has been proposed that haploinsufficiency at tumor sup-
Cancer arises via selective accumulation of genetic and epige- pressor loci is a likely mechanism for clonal expansion following
netic changes that confer a growth advantage on affected cells. an initial genetic hit (Quon and Berns, 2001). Thus, in contrast
Mechanistic studies of tumorigenesis have identified two dis- to the “two-hit” requirement originally proposed by Knudson,
tinct classes of loci that are frequent targets of genetic change haploinsufficiency at tumor suppressor loci would allow for man-
(Fearon and Vogelstein, 1990). These include conventional on- ifestation of pre-neoplastic or neoplastic phenotypes following
cogenes, which act in a dominant, gain-of-function manner and mutation of only a single allele of a tumor suppressor. Indeed,
often encode proteins that promote cell proliferation. The sec- recent work on tumor suppressor genes has demonstrated a
ond class consists of tumor suppressor genes, which elicit a role for haploinsufficiency at several loci, including p27, p53,
loss-of-function phenotype and encode proteins that limit cell Dmp1, and Nkx3.1 (Cook and McCaw, 2000; Fero et al., 1998;
growth or survival. As originally outlined by Knudson, both al- Venkatachalam et al., 1998; Inoue et al., 2001; Abdulkadir et
leles of prototypical tumor suppressor genes must be affected al., 2002). In these cases, mice lacking one allele of these tumor
to exact the pro-tumorigenic phenotype (Knudson, 1985). suppressors develop cancerous or pre-cancerous lesions de-
spite expression of the remaining wild-type allele. The relevanceThe kinetics of tumor development suggest that tumor for-
mation should be an almost impossibly difficult task. For in- of these findings in mouse models is supported by data from
patients in which loss of heterozygosity (LOH) is frequently ob-stance, by conservative estimate, a single cell requires four
genetic mutations in order to proliferate ad infinitum and evade served at the tumor suppressor locus, yet a single wild-type
allele is retained in the tumor (e.g., p27, p53, and Nkx3.1) (Pieten-pro-apoptotic stimuli (Renan, 1993). Therefore, at normal rates
of somatic mutation, the likelihood of tumor formation becomes pol et al., 1995; Davidoff et al., 1991; Voeller et al., 1997).
Haploid deletion of one tumor suppressor gene, Nkx3.1, isvanishingly small (Seshadri et al., 1987; Quon and Berns, 2001).
However, if the initial genetic lesion provides a selective growth frequently associated with prostate cancer and prostatic intra-
epithelial neoplasia (PIN) (Macoska et al., 1995; Bova et al.,advantage to the affected cell and its clonally expanding daugh-
S I G N I F I C A N C E
Recent studies have demonstrated that haploinsufficiency at tumor suppressor loci contributes to somatic tumorigenesis. Haploinsuffi-
cient loss of one such tumor suppressor, Nkx3.1, is associated with prostate cancer. Here we describe the effects of Nkx3.1 gene
dosage on target gene expression. These analyses establish a model for haploinsufficient tumorigenesis wherein loss of a single
Nkx3.1 allele results in major alterations in the expression of specific target genes. Such dramatic effects in gene regulation occur
because Nkx3.1 dosage modulates the probability of whether a target gene exists in the “on” versus the “off” state. These results
may account for some of the earliest genetic changes of prostate tumorigenesis and may reflect changes that occur in many types
of somatic tumor initiation.
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1993; He et al., 1997). Nkx3.1 encodes a homeodomain protein reduced, a finding consistent with the haploinsufficient Nkx3.1
phenotype.that is expressed specifically in the luminal epithelia of the pros-
Nkx3.1 protein levels followed a similar expression profiletate (He et al., 1997; Bieberich et al., 1996). Consistent with the
(Figure 1D). At 3 days post-TR, Nkx3.1 is coexpressed with theobservations of LOH in human PIN and prostate cancer, mice in
proliferation marker Ki-67. By 7 days post-TR, these dividingwhich a single Nkx3.1 allele is conditionally deleted in adulthood
cells exit the cell cycle, as evidenced by the dramatic reductiondevelop prostatic hyperplasia and PIN (Abdulkadir et al., 2002).
in Ki-67-positive cells. The differentiated luminal cells retainThe hyperplastic lesions of these mice, as well as conventional
Nkx3.1 expression. Altogether, these observations confirm theheterozygous mice, retain Nkx3.1 protein expression from the
luminal identity of the proliferating cell population, as Nkx3.1remaining wild-type allele (Bhatia-Gaur et al., 1999; Abdulkadir
has previously been established as a luminal epithelial marker.et al., 2002). These results imply the existence of Nkx3.1-regu-
Furthermore, the coexpression of Ki-67 and Nkx3.1 at 3 dayslated genetic circuits that modulate cell proliferation and are
post-TR indicates that Nkx3.1 does not, by itself, oppose prolif-exquisitely sensitive to Nkx3.1 dosage. In light of these observa-
eration in regenerating luminal epithelia.tions, we have utilized Nkx3.1/ and Nkx3.1/ mice to charac-
To test the effects of Nkx3.1 on growth arrest in the regener-terize the underlying mechanisms of gene dosage-dependent
ating prostate, we assayed Ki-67 expression in wild-type,tumor suppression. Here, we show that Nkx3.1 regulates the
Nkx3.1/, and Nkx3.1/ prostates by quantitative RT-PCRrate at which proliferating luminal epithelial cells exit the cell
(Figure 1C). In wild-type mice, Ki-67 expression peaks at 3cycle and that deletion of one or both alleles of Nkx3.1 extends
days post-TR and drops precipitously by day 7. This expressionthe transient proliferative phase of luminal cells during prostate
pattern correlates with luminal amplifying cell proliferation,regeneration. Using gene expression profiling, we have identi-
which peaks at day 3, and subsequent terminal differentiation,fied discrete haploinsufficient and nonhaploinsufficient clusters
which ensues by day 7. The Ki-67 profiles of Nkx3.1/ andof Nkx3.1 target genes. Intriguingly, haploinsufficient Nkx3.1
Nkx3.1/ mice exhibit an extended proliferative phase. Fortargets exhibit a varied response to the loss of one Nkx3.1 allele,
instance, at 7 days post-TR, Ki-67 levels are approximatelyas the expression of some targets is completely lost in the
5-fold higher in Nkx3.1/ prostates and 12-fold higher inNkx3.1/ prostate, whereas the expression of others is less
Nkx3.1/ prostates relative to wild-type. To determine whetheraffected. The quantitative effects observed at the level of the
the increase in Ki-67 mRNA levels reflects an increase in theentire prostate, in fact, reflect qualitative changes in target gene
number of proliferating cells, we counted the number of cellsexpression at the cellular level. Thus, a reduction in Nkx3.1
that incorporated Brdu in wild-type, Nkx3.1/, and Nkx3.1/
dosage predominantly affects the number of cells expressing
prostates at 3 and 7 days post-TR (Figures 2A–2F). The luminal
a given target gene. These findings have been integrated into
epithelial marker E-cadherin was used to confirm the luminal
a molecular model of haploinsufficiency and tumor initiation. identity of dividing and non-dividing cells. At three days post-TR,
we observed similar levels of Brdu incorporation in E-cadherin-
Results positive cells of wild-type, Nkx3.1/, and Nkx3.1/ prostates.
By 7 days post-TR, the fraction of Brdu-positive, E-cadherin-
Characterization of Nkx3.1 effects on regenerating positive, wild-type cells was dramatically reduced relative to
prostate epithelia 3 days post-TR. However, a much larger population of cells
Current models of epithelial turnover in the prostate hold that continued to divide in Nkx3.1/ and Nkx3.1/ prostates (p 
terminally differentiated luminal epithelial cells are derived from 0.05 and p  0.01, respectively). Thus, the loss of one or both
an androgen-responsive, transiently proliferating population of alleles of Nkx3.1 precludes timely withdrawal of luminal ampli-
luminal amplifying cells (English et al., 1987; Isaacs, 1987). Am- fying cells from the cell cycle. By 14 days post-TR, the extended
plifying cells, in turn, are believed to arise from prostatic stem proliferative phase results in extensive hyperplasia in the
cells. Evidence for the existence of luminal amplifying cells Nkx3.1-deficient prostate (Figures 2G and 2H).
comes, primarily, from the castration-testosterone replacement
(TR) model of prostate regeneration, where the implantation Identification of Nkx3.1 target genes
of testosterone pellets into castrated mice promotes a well- The effects of Nkx3.1 loss on androgen-mediated proliferative
characterized series of events in the prostate (summarized in changes indicate that Nkx3.1 and androgens act collaboratively
Figure 1A) (English et al., 1987; Isaacs, 1987). A dramatic burst to regulate epithelial cell proliferation and differentiation in the
of luminal cell proliferation is observed at 3 days post-TR, but regenerating prostate. The realization that these effects can be
by 7 days post-TR, these amplifying cells have terminally differ- observed, even after loss of a single Nkx3.1 allele, suggests the
entiated into secretory luminal epithelia. Given the hyperplastic presence of a subset of androgen target genes that are regulated
phenotype of Nkx3.1/ and Nkx3.1/ mice, we hypothesized in an Nkx3.1 dosage-sensitive manner. To identify Nkx3.1 target
that Nkx3.1 might regulate the proliferation and/or subsequent genes, we castrated 8-week-old wild-type, Nkx3.1/, and
differentiation of prostate epithelia in a dosage-sensitive man- Nkx3.1/ mice and implanted sustained-release testosterone
ner. To test this hypothesis, we castrated wild-type, Nkx3.1/, capsules at 14 days post-castration. Total RNA was harvested
and Nkx3.1/ mice at 8 weeks of age. At 14 days post-castra- at 0, 1, 3, 7, 14 days after testosterone treatment as well as
tion, sustained-release testosterone pellets were implanted, and from uncastrated 8-week-old mice. Two separate pools of RNA
tissues were collected at specific time points post-TR ranging from each time point, each containing RNA harvested from three
from 0–14 days (Figure 1A). In wild-type mice, Nkx3.1 mRNA individual mice, were used as templates to synthesize probes
was rapidly induced within 24 hr of TR (Figure 1B). Nkx3.1/ for microarray analysis. Genes that differ significantly between
prostates experienced a similar pattern of Nkx3.1 induction wild-type and Nkx3.1/ prostates throughout the timecourse
were identified by significance analysis of microarrays (SAM)post-TR, though the level of Nkx3.1 transcript was quantitatively
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Figure 1. Nkx3.1 regulates the transient proliferative phase of regenerating prostate epithelia
A: A schematic demonstrating the castration-testosterone replacement model of prostatic growth and differentiation.
B: Nkx3.1 expression was examined after castration-TR by qRT-PCR (solid lines [——], wild-type; dotted lines [………], Nkx3.1/; dashed lines [--------], Nkx3.1/).
Error bars show the SEM from N  5 prostates.
C: Ki-67 expression was examined after castration-TR by qRT-PCR (solid lines [——], wild-type; dotted lines [………], Nkx3.1/; dashed lines [--------], Nkx3.1/).
Error bars show the SEM from N  5 prostates.
D: Immunohistochemistry was performed on regenerating wild-type prostates for Ki-67 (red) and Nkx3.1. Note the presence of luminal epithelial cells that
coexpress Nkx3.1 and Ki-67 (yellow).
(Tusher et al., 2001). This algorithm identifies significantly altered and negatively regulated Nkx3.1 target genes (Figure 3). Quanti-
tative RT-PCR (qRT-PCR) analysis of several Nkx3.1 targetgenes from replicate data sets and calculates an expected false
discovery rate. From the Nkx3.1 data series, the SAM algorithm genes confirmed the validity of the methods used as all 15
genes analyzed were aberrantly regulated in Nkx3.1-deficientidentified a list of 57 significantly altered Nkx3.1 target genes
represented by 62 independent probe sets. The estimated false prostates (Figures 4 and 5 and data not shown).
Through this analysis, we found genes that were positivelydiscovery rate for this list was 1.1%. Hierarchical clustering of
the Nkx3.1 target genes revealed discrete clusters of positively regulated by Nkx3.1 and were therefore much lower in the ab-
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Figure 2. Nkx3.1 deficiency results in extended period of cell proliferation and luminal hyperplasia in the prostate following castration-TR
A–D: Cell proliferation was assayed by Brdu incorporation at 3 (A and B) and 7 (C and D) days post-TR. Dividing cells were labeled in wild-type (A and C)
and Nkx3.1/ (B and D) prostates during a 3 hr Brdu pulse. Immunohistochemistry was performed for Brdu (red) and the luminal epithelial cell marker
E-cadherin (green). Nuclei were counterstained with bisbenzimide (blue).
E and F: Wild-type, Nkx3.1/, and Nkx3.1/ tissues were labeled with Brdu and stained as described above. Percentages of Brdu-labeled luminal cells
were determined by examining 1000 E-cadherin-positive cells from prostates harvested at 3 and 7 days post-TR (E and F, respectively). Nkx3.1 allelic loss
resulted in a significant increase in Brdu incorporation at 7 days post-TR. Error bars represent the SEM for each group (N  2–3; *p  0.05; **p  0.01).
G and H: H&E staining revealed dramatic hyperplasia in the Nkx3.1/ prostate at 14 days post-TR (H) relative to wild-type (G).
sence of Nkx3.1 (e.g., intelectin, probasin). Genes were also lecular level. To identify the effects of Nkx3.1 gene dosage on
target gene expression, we analyzed their mRNA levels by qRT-identified that are normally repressed by Nkx3.1 and were there-
fore expressed at higher levels in Nkx3.1-deficient mice (e.g., PCR. This methodology afforded a highly quantitative measure-
ment of target gene expression that could be performed on aangiopoietin 2, elafin-like II). Interestingly, the expression of all
Nkx3.1-regulated genes identified in this study are influenced large number of animals in both the uncastrated and castration-
TR paradigms (N  5 for each time point and genotype). Forby the androgen status of the animal. This is consistent with
the observation that the expression of Nkx3.1 itself is regulated the uncastrated paradigm, we computed gene expression levels
by androgens, when gene activation is considered. However, in the Nkx3.1/ prostates as a percentage of wild-type levels,
the identification of genes, such as angiopoietin 2, that are with the wild-type level representing 100% expression and the
regulated by androgens only in the absence of Nkx3.1 was level in Nkx3.1/ representing 0% expression (Figure 4).
unexpected and suggests that Nkx3.1 functions as a selector These analyses revealed a spectrum of dosage sensitivity
that modulates expression of potential androgen target genes. among the Nkx3.1-activated genes. Genes such as probasin
Among the positively regulated Nkx3.1 target genes were known and the Riken clone 2210008A03 were relatively insensitive to
markers of prostatic luminal differentiation, including -micro- Nkx3.1 dosage, as expression levels in heterozygotes were ap-
seminoprotein (-MSP) and probasin. In humans, -MSP is one proximately 72% and 87% of wild-type expression, respec-
of three major prostatic secretory products (Abrahamsson et tively. At the other end of the spectrum, intelectin expression
al., 1988). Human prostate tumors exhibit reduced levels of was essentially lost in the prostates from both Nkx3.1 heterozy-
-MSP, as might be predicted given the frequent loss of Nkx3.1 gotes and homozygotes (Figure 4). These extremes flanked a
protein expression in prostate cancer (Tsurusaki et al., 1998). spectrum of dosage-sensitive responses that included Riken
Probasin is a well-studied androgen target in the rodent prostate clone 3300002C04, fucosyltransferase 8, and PDZ domain con-
(Johnson et al., 2000). Nkx3.1 regulation of these genes is con- taining protein 1, which were expressed in the Nkx3.1-heterozy-
sistent with its role as a mediator of luminal differentiation in gous prostate at 55%, 31%, and 16% of wild-type levels, re-
the prostate. spectively. In general, relative responses in the castration/TR
paradigm correlated well with those observed in the uncastrated
paradigm (Figure 4). Furthermore, the sensitivity of a given geneVariable dosage sensitivity among Nkx3.1 target genes
The Nkx3.1 target genes described above provide a unique to Nkx3.1 gene dosage did not appear to correlate with its wild-
type expression level. For example, intelectin is highly dosageopportunity to track the effects of haploinsufficiency at the mo-
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Figure 3. Expression profiles of genes that were significantly altered in Nkx3.1-deficient prostates
Nkx3.1 target genes were identified by SAM analysis of prostate expression profiles from wild-type, Nkx3.1/, and Nkx3.1/ mice. For each of the 62
significantly changed probe sets (representing 57 independent genes), the average expression profiles from replicate experiments using prostates from
wild-type, Nkx3.1/, and Nkx3.1/ mice were hierarchically clustered. Heat map colors reflect log(2) fold-change values relative to expression in the wild-
type (uncastrated) or wild-type day 0 (castration-TR) measurements. Distinct groups of positively (orange) and negatively (pink) regulated Nkx3.1 target
genes are apparent from the cluster dendogram shown to the left of the heat map. Underlined gene names denote expression profiles that were
subsequently examined, and in each case confirmed, by qRT-PCR (N  5).
sensitive, yet its expression in wild-type prostate is higher than sponse to increasing levels of one or more transcription factors.
An alternative to the graded model, however, is a stochastic,Riken 221008A03 but lower than probasin. Intriguingly, the neg-
atively regulated Nkx3.1 target genes WSU-176, sushi-repeat binary model of transcriptional activation (Fiering et al., 2000).
The stochastic model implies that genes exist in either an “on”protein X, angiopoietin 2, and elafin-like II did not display a
similar spectrum of dosage sensitivity (Figure 5). In fact, the or an “off” state and that transcription factors regulate the prob-
ability of a gene occupying either state. While these models areexpression of these genes in the Nkx3.1/ prostate closely
resembled that found in wild-type prostate, with target gene not mutually exclusive, they raise two possible explanations for
the spectrum of Nkx3.1 target gene dosage sensitivity describedactivation observed only in Nkx3.1/ prostates.
above. Consistent with the graded model of transcriptional acti-
Non-uniform expression patterns vation, dosage sensitive reductions in target gene levels could
of Nkx3.1-activated target genes be uniform in all luminal cells. Alternatively, the stochastic model
Transcriptional regulation is commonly discussed as a graded would predict a non-uniform reduction in Nkx3.1 target gene
levels, with reduced Nkx3.1 gene dosage resulting in a de-process with promoter activity increasing proportionally in re-
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Figure 4. Nkx3.1 haploinsufficiency affects expression of a subset of positively regulated Nkx3.1 target genes
Nkx3.1 target gene expression was analyzed by qRT-PCR in prostates taken from the uncastrated (top) and castration-TR (bottom) paradigms. For both
paradigms, expression changes are presented as fold changes relative to wild-type uncastrated or wild-type, 0 days post-TR values (solid lines [——], wild-
type; dotted lines [………], Nkx3.1/; dashed lines [--------], Nkx3.1/). Error bars reflect the SEM from N  5 mice. Percentages of dosage sensitivity for
Nkx3.1/ prostates, given below each graph, were calculated by setting wild-type expression levels to 100% and Nkx3.1/ levels to 0%.
Figure 5. Nkx3.1 represses expression of a subset of androgen-regulated genes
Nkx3.1 target gene expression was analyzed by qRT-PCR as above. Average fold-change values are given relative to wild-type uncastrated (top) or wild-
type, 0 days post-TR values (bottom) (solid lines [——], wild-type; dotted lines [………], Nkx3.1/; dashed lines [--------], Nkx3.1/). Error bars reflect the SEM
from N  5 mice.
creased fraction of cells that express a particular target gene opposite ends of the dosage sensitivity spectrum. Probasin is
relatively insensitive to the loss of one Nkx3.1 allele. It is highly(at or near wild-type levels) relative to the fraction of cells that
do not express the target gene at all. expressed in both wild-type and Nkx3.1/ prostates, and even
Nkx3.1/ prostates retain some probasin expression (Figure 4To distinguish between these two models, we performed in
situ hybridization on two Nkx3.1 target genes selected from and data not shown). Intelectin occupies the opposite end of
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Figure 6. Stochastic, Nkx3.1 gene dosage-sensi-
tive alterations in the expression patterns of
Nkx3.1 target genes
The expression patterns of intelectin and proba-
sin were examined in wild-type, Nkx3.1/, and
Nkx3.1/ prostates by in situ hybridization. For
intelectin, note the mosaic pattern of cells that
express intelectin and cells that do not in the
wild-type prostate. A similar mosaic pattern can
be seen for probasin in the Nkx3.1/ prostate.
Immunohistochemistry with anit-Nkx3.1 antibod-
ies demonstrated a uniform pattern of Nkx3.1
protein expression in wild-type and Nkx3.1/
prostates (bottom panels).
the dosage sensitivity spectrum, as it is not expressed in either ences the stochastic probability rather than the absolute level
the Nkx3.1/ or Nkx3.1/ prostate (Figure 4). In situ hybridiza- of target gene activity in a given cell.
tion experiments revealed non-uniform expression patterns for
both probasin and intelectin (Figure 6). While probasin is ex- Discussion
pressed uniformly in wild-type and Nkx3.1/ prostate, the
Nkx3.1/ prostate contains a heterogeneous population of pro- The molecular events that occur during the earliest stages of
basin-expressing and nonexpressing luminal epithelia (Figure tumorigenesis remain enigmatic. However, it is clear that the
6). Interestingly, wild-type prostate presents a similarly hetero- first genetic “hit” during tumor development must convey a
geneous pattern of expression with respect to intelectin, with growth advantage to the affected cell, as the likelihood of accu-
only a subset of wild-type luminal epithelia expressing the intel- mulating multiple genetic lesions concurrently in a single, normal
ectin transcript. We did not observe intelectin expression in cell is extremely low (Quon and Berns, 2001). Subsequent prolif-
either Nkx3.1/ or Nkx3.1/ prostates by in situ hybridization. eration of the affected cells then propagates the initial mutation,
Thus, there is a bimodal distribution of expressing and nonex- thus creating a reservoir of cells that are more susceptible to
pressing cells for both probasin and intelectin that contrasts
the damage caused by a second independent mutation (Quon
with the relatively uniform distribution of Nkx3.1 protein in both
and Berns, 2001). But how, mechanistically, might an initiatingwild-type and Nkx3.1/ prostates (Figure 6). The probasin ex-
lesion be significant enough to enhance proliferation yet subtlepression pattern is particularly supportive of stochastic gene
enough to avoid triggering the anti-tumorigenic safeguards ofregulation as it is a highly expressed, and therefore easily de-
well-differentiated cells? Perhaps the more subtle alterations intected, transcript that is lost entirely in only a subset of Nkx3.1/
cell growth emanating from dosage-sensitive loci might play aluminal cells. Because these cells lack both copies of the Nkx3.1
role in this process. For example, if haploinsufficiency at tumori-gene, the probasin mosaic cannot be attributed to an intercellu-
genic loci is indeed central to tumor initiation, then small reduc-lar variance of Nkx3.1 protein levels. Rather, Nkx3.1 deficiency
tions in levels of a tumor suppressor might result in changes inappears to reduce, but not nullify, the probability of probasin
gene expression and increased proliferation. The results of ourpromoter activity. While we cannot rule out graded effects on
analysis of Nkx3.1 deficency suggest that loss of a single alleleNkx3.1 target gene expression, the intelectin and probasin ex-
can dramatically influence expression of selected target genespression patterns are most consistent with a model for gene
induction wherein Nkx3.1 gene dosage predominantly influ- and result in pre-neoplastic lesions.
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Figure 7. A model depicting the effects of haploinsufficiency on tumor initiation
During normal epithelial turnover, mutation at a single Nkx3.1 allele in the amplifying cell population results in stochastic inactivation of dosage-sensitive
Nkx3.1 target genes and a concomitant failure to exit the transient proliferative phase. These defects lead to an expanded population of dividing cells
that serve as targets for subsequent genetic change. Additional genetic alterations accompany a transition from hyperplastic cell populations, carrying
the initiating “hit” to the Nkx3.1 locus, to PIN lesions that harbor multiple mutations.
Nkx3.1 regulates cell cycle exit during tate. Nkx3.1 haploinsufficiency results in global luminal hyper-
plasia in young adult mice, circa 8 weeks of age. Focal PINluminal cell regeneration
Nkx3.1-deficient mice develop prostatic hyperplasia as young lesions do not become apparent until 6 months of age in
Nkx3.1/ prostates, though compound heterozygosity at theadults that progresses to PIN over time (Abdulkadir et al., 2002;
Bhatia-Gaur et al., 1999). Mice lacking only a single allele of PTEN locus has been shown to expedite the process of PIN
formation (Kim et al., 2002). A similar explanation has beenNkx3.1 develop similar, though often less severe phenotypes.
Furthermore, mice in which an allele of Nkx3.1 is conditionally offered to describe how the expanded lymphoid compartment
of Bcl-2-overexpressing mice might facilitate lymphomagenesisdeleted in the prostate in adulthood also develop hyperplasia
and PIN, consistent with the frequent LOH occurring at the (McDonnell et al., 1989). Transgenic overexpression of Bcl-2 in
lymphoid cells results in follicular hyperplasia that, over time,Nkx3.1 locus in human PIN lesions (Abdulkadir et al., 2002). It
has therefore been proposed that Nkx3.1 either establishes or progresses to diffuse large-cell lymphoma (McDonnell and Kors-
meyer, 1991). In this model, monoclonal tumors arise from amaintains luminal epithelia in a growth-arrested state and that
the loss of one or both alleles results in excessive luminal cell polyclonal population of pre-neoplastic cells. Ongoing lineage
tracing studies should help determine whether PIN lesions inproliferation (Abdulkadir et al., 2002; Bhatia-Gaur et al., 1999).
The castration-TR model has allowed for a more thorough analy- Nkx3.1/ and Nkx3.1/ mice are, in fact, derived from poly-
clonal reservoirs of transient proliferating cells.sis of the dosage-sensitive Nkx3.1 phenotype, as it establishes
a relatively synchronous population of proliferating and differ-
entiating luminal epithelial cells in the prostate. Analysis of this Nkx3.1 modulates androgen target gene activity
The extended transient proliferative phase observed inmodel indicates that Nkx3.1-deficient luminal cells, and
Nkx3.1/ cells to a lesser extent, fail to appropriately exit the Nkx3.1/ and Nkx3.1/ luminal cells suggests that Nkx3.1
and androgens cooperatively regulate gene expression duringtransient proliferating state. Unlike wild-type prostate epithelia,
Nkx3.1/ and Nkx3.1/ luminal epithelial cells continue prolif- prostate regeneration. Indeed, both positively and negatively
regulated Nkx3.1 target genes are simultaneously regulated byerating for at least one week after testosterone replacement.
This extended proliferation results in luminal hyperplasia that is androgens. Preliminary scrutiny of the Nkx3.1 target promoters
suggests that Nkx3.1 and androgen receptor (AR) coregulationclearly evident in Nkx3.1/ prostates by 14 days post-TR.
Despite the delay in terminal differentiation, Nkx3.1-deficient is direct. We used Transfac 6.2 matrices to screen the non-
repeat regions of each target gene promoter for 500 base paircells do ultimately growth arrest following testosterone replace-
ment, as Ki-67 expression levels in the Nkx3.1/ prostate ap- windows that contain both AR and Nkx3.1 consensus sites.
In a majority of target promoters, including the intelectin andproach wild-type levels by 14 days post-TR. How then might
Nkx3.1 allelic loss establish a genetic environment conducive to probasin promoters, this approach identified putative Nkx3.1
and AR binding sites located within 500 base pairs of one an-further transformation? A likely explanation is that the extended
transient proliferative state of Nkx3.1/ and Nkx3.1/ cells other (data not shown). These findings support the hypothesis
that Nkx3.1 and AR cooperatively regulate common cis-ele-results in an enlarged population of proliferating cells in the
prostate, and therefore an enlarged target population for subse- ments, and further molecular characterization of these elements
is clearly warranted.quent genetic alterations (Figure 7). This multistep model is
consistent with the natural history of PIN formation in the pros- Androgens play a critical role in the growth and maintenance
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of the prostate, and androgen signaling is a predominant target target gene. In the case of tumor suppression, this phenotype
for prostate cancer therapeutics. Thus, the androgen-depen- might manifest itself as an extended proliferative state that could
dent expression profiles of Nkx3.1 target genes further implicate eventually lead to hyperplasia and neoplasia.
Nkx3.1 as a modulator of crucial mitogenic pathways in the Altogether, the results presented here suggest a mechanism
prostate. The disruption of these pathways could account for for initiating the multistep process of tumor progression in the
the haploinsufficient hyperplasia and PIN phenotypes observed prostate (Figure 7). At the point of tumor initiation, the loss of a
in the Nkx3.1 mouse model and the frequent LOH observed at single Nkx3.1 allele results in stochastic inactivation of dosage-
the Nkx3.1 locus in human prostate tumors. sensitive Nkx3.1 targets that, in turn, extend the proliferative
phase of luminal amplifying cells. Clonally expanded populations of
Dosage sensitivity of Nkx3.1 target genes these undifferentiated cells could accrue additional genetic lesions
The proliferative phenotype of Nkx3.1/ epithelial cells raises that would facilitate progression to PIN and prostate cancer.
the question of how, at the molecular level, heterozygous cells Further functional characterization of the dosage-sensitive and
might recapitulate a null phenotype. We have addressed this dosage-insensitive Nkx3.1 targets will help illuminate their spe-
question by characterizing the effects of Nkx3.1 haploinsuffi- cific contributions to the differentiation and immortalization
ciency on Nkx3.1 target gene expression using qRT-PCR and pathways outlined above. Likewise, comprehensive analyses of
in situ hybridization. The sensitivity of Nkx3.1 targets to the loss Nkx3.1 target gene promoters should offer crucial insights into
of one or both Nkx3.1 alleles was variable, with a spectrum the cis-regulatory underpinnings of dosage sensitivity. As haplo-
of dosage sensitivity observed among the positively regulated insufficiency at tumor suppressor loci is, most likely, a common
Nkx3.1 target genes. Some genes, such as intelectin or PDZ1, occurrence during somatic tumorigenesis, the stochastic effects
are highly sensitive to mono-allelic loss of Nkx3.1, whereas of Nkx3.1 dosage on target gene expression may exemplify a
others, such as Riken 2210008A03 and probasin, are relatively widespread paradigm for tumor initiation. Accordingly, the
refractory to haploinsufficient effects. The expression pattern
Nkx3.1 model serves as a platform for further investigating the
of Nkx3.1 target genes is also informative, as depending on the
mechanism of haploinsufficiency and its role in promoting tu-
Nkx3.1 dosage, both intelectin and probasin are expressed in
morigenesis.a mosaic pattern that includes both expressing and nonexpress-
ing prostate epithelial cells. The simplest and most reasonable Experimental procedures
explanation for the probasin and intelectin expression patterns
is that they are regulated by stochastic, binary promoters. In Animal procedures
The Nkx3.1 mutant mice used in this study have been described previouslythis scenario, Nkx3.1 dosage influences the probability of target
(Abdulkadir et al., 2002). For all castration-testosterone replacement experi-gene activation rather than the level of expression. The broad
ments, mice were castrated at 8 weeks of age and allowed to recover. Atspectrum of Nkx3.1 dosage sensitivity observed in the identified
14 days post-castration, testosterone was replaced by implanting 2 cmsubset of Nkx3.1 target genes suggests that the dosage effects
silastic capsules (1.5 mm inside diameter, Fisher) filled with 50 mg of testos-vary depending on the architecture of the target gene promoter.
terone propionate (Sigma). At the indicated times after testosterone replace-
The observations presented here find precedent in previous ment, mice were killed by cervical dislocation and their prostates were
investigations of graded versus stochastic promoter activity (Fier- harvested as described below. All uncastrated mice were sacrificed at 8
ing et al., 2000). The liver enzymes carbamoylphosphate synthe- weeks of age unless otherwise indicated.
tase and phosphoenolpyruvate carboxykinase accumulate sto-
Immunohistochemistry and in situ hybridizationchastically in embryonic hepatocytes in response to hormonal
For double labeling immunohistochemistry experiments (Nkx3.1/Ki-67 orstimuli (van Roon et al., 1989). Likewise, cultured mammalian
E-cadherin/Brdu), paraformaldehyde fixed tissues were stained as describedcells carrying a glucocorticoid-responsive lacZ reporter gene
for use of two primary antibodies derived from the same species (Shindlerexpress -galactosidase at levels proportional to dexametha-
and Roth, 1996). Briefly, tissues were stained with the first primary antibody
sone concentration (Ko et al., 1990). In this study, assays of at concentrations sufficiently low so as to prevent detection without signal
-galactosidase activity at the cellular level revealed a heteroge- amplification (rabbit anti-Nkx3.1, 1:200; or mouse anti-E-cadherin, Trans-
neous population of expressing and nonexpressing cells that duction Laboratories, 1:10,000). Horseradish peroxidase-conjugated sec-
resembles the pattern observed for Nkx3.1 target genes in the ondary antibodies were used in conjunction with tyramide signal amplifica-
tion to visualize the first antigen (TSA-plus fluorescein kit, Perkin Elmer).prostate. This heterogeneity could not be attributed to intrinsic
Tissues were subsequently stained with antibodies to the second antigenproperties of the cells, as colonies derived from single cell clones
of interest (rabbit anti-Ki-67, Novacastra, 1:1000; or mouse anti-Brdu, Roche,still exhibited heterogeneous-galactosidase expression. Thus,
1:200) and visualized with Cy3-conjugated secondary antibodies.the effects on gene expression resulting from loss of a single
In situ hybridization experiments were performed using digoxigenin-
Nkx3.1 allele are consistent with previous observations of sto- labeled riboprobes on paraformaldehyde fixed, cryoprotected frozen sec-
chastic, dosage-dependent promoter activity. tions. In situ hybridization probes corresponded to nt 282–731 of the mouse
The relationship between Nkx3.1 dosage and stochastic probasin mRNA and nt 1–506 of the mouse intelectin mRNA.
target gene activity is particularly pertinent when considering
Brdu incorporation assayshow a null molecular phenotype might occur in cells heterozy-
Adult wild-type, Nkx3.1/, and Nkx3.1/ mice were castrated and testos-gous at a particular locus. Because Nkx3.1 dosage affects the
terone pellets were implanted as described above. At 3 or 7 days post-TR,probability of target gene activation, it is reasonable to predict
mice (n  2–3 per time point per genotype) were injected intraperitoneallythat the loss of a single Nkx3.1 allele would similarly enhance
with 6 mg of Brdu and sacrificed 3 hr later. Prostates were fixed overnight
the probability of complete inactivation of a given target gene in 4% paraformaldehyde and stained for Brdu and E-cadherin as described
in luminal epithelial cells. Inactivation of a given target gene above. For each prostate, 1000 E-cadherin-positive cells were counted
would, at the level of the affected cell, generate a null phenotype from multiple sections to determine the fraction of Brdu-positive luminal
epithelial cells.for the processes regulated by the protein encoded by that
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